0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Multiply Recurrent Solitary Fibrous Tumor of the Orbit Without Malignant Degeneration: A 45-Year Clinicopathologic Case Study FREE

Gregory J. Griepentrog, MD; Gerald J. Harris, MD; Eduardo V. Zambrano, MD
[+] Author Affiliations

Author Affiliations: Section of Oculofacial and Orbital Surgery, Department of Ophthalmology (Drs Griepentrog and Harris) and Section of Musculoskeletal Pathology, Department of Pathology (Dr Zambrano), Medical College of Wisconsin, Milwaukee.


JAMA Ophthalmol. 2013;131(2):265-267. doi:10.1001/2013.jamaophthalmol.69.
Text Size: A A A
Published online

Solitary fibrous tumor (SFT) is a rare mesenchymal spindle cell neoplasm originally described in the pleura and subsequently identified in a number of extrathoracic sites. Orbital SFT was first described in 1994; since then, more than 100 cases have been reported or reclassified with that diagnosis.1,2 Only 4 patients were younger than 10 years when first diagnosed as having orbital SFT. While most reports describe a benign clinical course, rare cases of primary malignant orbital SFT have also been documented. This led the World Health Organization to classify SFT as a neoplasm of intermediate biological potential (locally aggressive, rarely metastasizing).3,4 Increased cellular atypia or mitotic activity in recurrent lesions following primary excision of orbital SFTs has also been described, suggesting that complete initial resection is a critical prognostic factor in preventing malignant degeneration.1,47 We describe a patient with orbital SFT whose proptosis was first recognized at age 9 years and who underwent surgical excision at various institutions at ages 12, 22, and 52 years. To our knowledge, this represents the longest histopathologically documented follow-up of a patient with orbital SFT.

In 1967, a 9-year-old girl with painless left proptosis underwent an exploratory craniotomy in which no tumor was found. With a presumptive diagnosis of orbital hemangioma, she was treated with external beam radiation. In 1970, she underwent an orbitotomy with removal of a 4.0 × 2.5-cm lobulated, reddish-blue mass, described as a hemangioma. Recurrent proptosis was noted in 1980, and a lateral orbitotomy with bone flap was performed with removal of a 5-cm lesion. At that time, review at the Armed Forces Institute of Pathology of the 1970 and 1980 specimens yielded a diagnosis of fibrous histiocytoma.

In 2010, the patient was referred to our institution with a history of gradually recurrent proptosis and recent-onset diplopia. Orbital imaging demonstrated a large, homogeneously enhancing mass that filled the inferotemporal extraconal and intraconal left orbit (Figure 1). A lower fornix-approach orbitotomy was performed with removal of all gross tumor (Figure 2). Histologic sections showed a proliferation of spindle cells with eosinophilic cytoplasm, poorly defined cytoplasmic borders, and elongated nuclei with small eosinophilic nucleoli, arranged in short intersecting fascicles in a “patternless pattern” (Figure 3A). Occasional hemangiopericytic thin-walled vessels were present (Figure 3B). Rare mitotic figures were seen, with no atypical forms, areas of necrosis, or cytologic atypia identified. Immunohistochemical staining revealed that neoplastic cells were strongly and diffusely positive for CD34 (Figure 3C), CD99, and Bcl-2 and negative for smooth muscle actin, muscle-specific actin, desmin, S-100 protein, and AE1/AE3 cytokeratins, supporting the diagnosis of SFT. The patient did well following gross tumor excision and remained symptom free at 1 year.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Axial (A) and coronal (B) computed tomographic images demonstrating a left 2.7 × 1.7 × 1.6-cm mass isodense to muscle (A) and with homogeneous intense contrast enhancement (B).

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Gross tumor following excision.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 3. Short intersecting fascicles of cytologically bland spindle cells arranged in a “patternless pattern” (hematoxylin-eosin) (A), dilated hemangiopericytic thin-walled vessels (hematoxylin-eosin) (B), and positive CD34 immunostaining (C) (original magnification ×200).

We are aware of 4 cases of recurrent SFT that showed increased cellularity, atypia, or mitotic rate compared with the primary lesions, suggesting malignant transformation with time.47 Such cases have led to the conclusion that the most important prognostic factor is not the initial histologic appearance but rather complete primary resection.1 In those reports, the interval between initial tumor excision and final recurrent tumor excision ranged from 6 months to 7 years. Our case provides further insight into the heterogeneous histologic and clinical behavior of these tumors. After an interval that included initial recognition of proptosis at age 9 years and multiple surgical resections as late as age 52 years, there were no histopathologic features to suggest malignant transformation. A limitation of this study is that the 1970 and 1980 outside histopathologic material is no longer available to document a uniform diagnosis throughout the 45-year course. However, a 1980 Armed Forces Institute of Pathology review of that material did yield a diagnosis of orbital fibrous histiocytoma, an entity that has been more recently reclassified as orbital SFT in many cases.2 Our case suggests that incompletely excised, long-standing SFTs do not necessarily increase in biological aggressiveness.

Correspondence: Dr Griepentrog, Section of Oculofacial and Orbital Surgery, Department of Ophthalmology, Medical College of Wisconsin, 925 N 87th St, Milwaukee, WI 53226 (ggriepentrog@mcw.edu).

Author Contributions: Drs Griepentrog and Harris had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported in part by an unrestricted grant from Research to Prevent Blindness.

Krishnakumar S, Subramanian N, Mohan ER, Mahesh L, Biswas J, Rao NA. Solitary fibrous tumor of the orbit: a clinicopathologic study of six cases with review of the literature.  Surv Ophthalmol. 2003;48(5):544-554
PubMed   |  Link to Article
Furusato E, Valenzuela IA, Fanburg-Smith JC,  et al.  Orbital solitary fibrous tumor: encompassing terminology for hemangiopericytoma, giant cell angiofibroma, and fibrous histiocytoma of the orbit: reappraisal of 41 cases.  Hum Pathol. 2011;42(1):120-128
PubMed   |  Link to Article
Fletcher CDM, ed, Unni KK, ed, Mertens F, edPathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002
Manousaridis K, Stropahl G, Guthoff RF. Recurrent malignant solitary fibrous tumor of the orbit [in German].  Ophthalmologe. 2011;108(3):260-264
PubMed   |  Link to Article
Dorfman DM, To K, Dickersin GR, Rosenberg AE, Pilch BZ. Solitary fibrous tumor of the orbit.  Am J Surg Pathol. 1994;18(3):281-287
PubMed   |  Link to Article
Romer M, Bode B, Schuknecht B, Schmid S, Holzmann D. Solitary fibrous tumor of the orbit: two cases and a review of the literature.  Eur Arch Otorhinolaryngol. 2005;262(2):81-88
PubMed   |  Link to Article
Hayashi S, Kurihara H, Hirato J, Sasaki T. Solitary fibrous tumor of the orbit with extraorbital extension: case report.  Neurosurgery. 2001;49(5):1241-1245
PubMed

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Axial (A) and coronal (B) computed tomographic images demonstrating a left 2.7 × 1.7 × 1.6-cm mass isodense to muscle (A) and with homogeneous intense contrast enhancement (B).

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Gross tumor following excision.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 3. Short intersecting fascicles of cytologically bland spindle cells arranged in a “patternless pattern” (hematoxylin-eosin) (A), dilated hemangiopericytic thin-walled vessels (hematoxylin-eosin) (B), and positive CD34 immunostaining (C) (original magnification ×200).

Tables

References

Krishnakumar S, Subramanian N, Mohan ER, Mahesh L, Biswas J, Rao NA. Solitary fibrous tumor of the orbit: a clinicopathologic study of six cases with review of the literature.  Surv Ophthalmol. 2003;48(5):544-554
PubMed   |  Link to Article
Furusato E, Valenzuela IA, Fanburg-Smith JC,  et al.  Orbital solitary fibrous tumor: encompassing terminology for hemangiopericytoma, giant cell angiofibroma, and fibrous histiocytoma of the orbit: reappraisal of 41 cases.  Hum Pathol. 2011;42(1):120-128
PubMed   |  Link to Article
Fletcher CDM, ed, Unni KK, ed, Mertens F, edPathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002
Manousaridis K, Stropahl G, Guthoff RF. Recurrent malignant solitary fibrous tumor of the orbit [in German].  Ophthalmologe. 2011;108(3):260-264
PubMed   |  Link to Article
Dorfman DM, To K, Dickersin GR, Rosenberg AE, Pilch BZ. Solitary fibrous tumor of the orbit.  Am J Surg Pathol. 1994;18(3):281-287
PubMed   |  Link to Article
Romer M, Bode B, Schuknecht B, Schmid S, Holzmann D. Solitary fibrous tumor of the orbit: two cases and a review of the literature.  Eur Arch Otorhinolaryngol. 2005;262(2):81-88
PubMed   |  Link to Article
Hayashi S, Kurihara H, Hirato J, Sasaki T. Solitary fibrous tumor of the orbit with extraorbital extension: case report.  Neurosurgery. 2001;49(5):1241-1245
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections